Lunresertib/Camonsertib Combo Yields Promising Response in Gynecologic Cancers
The combination use of lunresertib (RP-6306) and camonsertib (RP-3500) derived clinical benefit among patients with heavily pretreated endometrial cancer and platinum-resistant ovarian cancer, according to data from the gynecologic expansion cohort of the …